Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma
Kinaset Therapeutics To Evaluate Candidate
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
You may also be interested in...
Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
In top-line results from the Phase III NAVIGATOR study, AstraZeneca/Amgen’s human monoclonal antibody tezepelumab has significantly reduced disease exacerbations in patients with severe asthma regardless of their type of inflammation, including those with low eosinophil counts.